Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic reported an impressive financial performance for the fiscal Q1 ended December 26, 2020, with revenues soaring by 89.3% to $1.61 billion. The growth was driven by a 457.6% surge in molecular diagnostics revenue, fueled by demand for SARS-CoV-2 tests. The company also announced acquisitions of Biotheranostics and SOMATEX, with cash flow from operations at $650 million. Although net income rose to $654.4 million, net margins declined by 480 bps. Hologic expects continued strong performance for Q2 with guidance of $1.50 - $1.56 billion in revenue.
Hologic, Inc. (Nasdaq: HOLX) will announce its financial results for Q1 of fiscal 2021 on January 27, after market close. A conference call is set for 4:30 p.m. ET, accessible at 888-204-4368 (U.S.) or +1 323-994-2093 (international). Participants are encouraged to join 5-10 minutes early. The call will also be available via webcast on Hologic's investor website and archived for 30 days.
Hologic is dedicated to advancing women's health through innovative medical technologies.
Hologic, Inc. (Nasdaq: HOLX) announced preliminary revenue results for Q1 fiscal 2021, expecting revenues of approximately $1,609.8 million, up 89.3% year-over-year. This exceeds prior guidance of $1,350-$1,425 million. Diagnostics revenue surged 262.2% to $1,128.2 million, fueled by nearly 30 million COVID-19 tests. The company will report full results on January 27, 2021, and announced a $1 billion share repurchase plan while paying off $250 million of debt.
Hologic, Inc. (Nasdaq: HOLX) has announced its acquisition of Biotheranostics, Inc. for approximately $230 million. This strategic move aims to enhance Hologic's position in the oncology sector, particularly in women's health diagnostics. Biotheranostics offers advanced molecular diagnostic tests for breast and metastatic cancers, which align with Hologic's broader goals. The acquisition is projected to be dilutive to Hologic's non-GAAP earnings in 2021 but expected to break-even in 2022 and become accretive thereafter. The transaction is anticipated to close in February 2021, pending regulatory approvals.
Hologic, Inc. (Nasdaq: HOLX) has completed the acquisition of SOMATEX Medical Technologies GmbH for approximately $64 million. This move aims to bolster Hologic’s breast health care solutions, expanding its biopsy portfolio and enhancing sales presence, particularly in Europe. SOMATEX specializes in biopsy site markers, which are expected to generate about $13 million in revenue in 2020. The acquisition is anticipated to positively impact Hologic’s non-GAAP earnings per share starting in the current fiscal year.
Hologic, Inc. (Nasdaq: HOLX) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 11:40 a.m. ET. The live webcast of the presentation can be accessed via the investors section of Hologic’s website and will remain available for 30 days post-event. Hologic is a medical technology company focused on enhancing women's health through early detection and treatment.
Hologic, Inc. (Nasdaq: HOLX) announced FDA clearance for its new Genius AI™ Detection technology, aimed at enhancing breast cancer detection through advanced deep learning software. This system assists radiologists in identifying subtle potential cancers in breast tomosynthesis images, reportedly increasing sensitivity and reducing false-positive rates compared to previous CAD products. It operates directly on the mammography system's workstation, improving workflow and patient outcomes. This innovation represents a significant step forward in early breast cancer detection, aligning with Hologic's commitment to women's health.
Hologic, Inc. (Nasdaq: HOLX) will showcase its breast and skeletal health products at the virtual 106th RSNA Annual Meeting from Nov. 29 to Dec. 5. The company aims to provide innovations that enhance workflow efficiency and patient outcomes. Hologic ranked first in customer satisfaction for mammography service according to the 2020 IMV ServiceTrack™ report. The virtual event will offer product demonstrations and educational sessions, reflecting Hologic's commitment to advancing women's healthcare despite pandemic challenges.
Hologic, Inc. (Nasdaq: HOLX) will present virtually at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, at 4:20 p.m. Eastern Time. The presentation will be available via a live webcast on Hologic's investor website and can be accessed for 30 days post-event. Hologic is dedicated to enhancing women's health through innovative medical technologies, focusing on early detection and treatment. For more details, visit www.hologic.com.
Hologic, Inc. (Nasdaq: HOLX) received FDA approval for the Aptima® HIV-1 Quant Dx assay, making it the first dual-claim assay in the U.S. for HIV diagnosis and viral load monitoring. Previously approved for viral load monitoring in 2016, this molecular test operates on the Panther® system, providing reliable results across various HIV-1 groups. The approval is expected to enhance patient care by enabling immediate treatment initiation and assisting clinical labs in consolidating testing processes. There are around 1.2 million people living with HIV in the U.S.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
